vs
NORTHERN OIL & GAS, INC.（NOG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是NORTHERN OIL & GAS, INC.的1.3倍（$772.1M vs $610.2M），Revvity净利率更高（12.7% vs -11.6%，领先24.3%），Revvity同比增速更快（5.9% vs -72.6%），Revvity自由现金流更多（$161.8M vs $43.2M），过去两年Revvity的营收复合增速更高（9.0% vs 4.3%）
Marathon Oil Corporation是一家美国油气勘探开发企业，核心业务涵盖油气资源的勘探、开采与运营，2024年11月被康菲石油收购，相关业务与资产已并入康菲石油体系。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
NOG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$610.2M
营收增速更快
RVTY
高出78.4%
-72.6%
净利率更高
RVTY
高出24.3%
-11.6%
自由现金流更多
RVTY
多$118.6M
$43.2M
两年增速更快
RVTY
近两年复合增速
4.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $610.2M | $772.1M |
| 净利润 | $-70.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | -11.6% | 12.7% |
| 营收同比 | -72.6% | 5.9% |
| 净利润同比 | -198.7% | 3.9% |
| 每股收益（稀释后） | $-0.73 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NOGRVTY
| Q1 26 | $610.2M | — | ||
| Q4 25 | $610.2M | $772.1M | ||
| Q3 25 | $556.6M | $698.9M | ||
| Q2 25 | $706.8M | $720.3M | ||
| Q1 25 | $602.1M | $664.8M | ||
| Q4 24 | $515.0M | $729.4M | ||
| Q3 24 | $753.6M | $684.0M | ||
| Q2 24 | $560.8M | $691.7M |
净利润NOGRVTY
| Q1 26 | $-70.7M | — | ||
| Q4 25 | $-70.7M | $98.4M | ||
| Q3 25 | $-129.1M | $46.7M | ||
| Q2 25 | $99.6M | $53.9M | ||
| Q1 25 | $139.0M | $42.2M | ||
| Q4 24 | $71.7M | $94.6M | ||
| Q3 24 | $298.4M | $94.4M | ||
| Q2 24 | $138.6M | $55.4M |
毛利率NOGRVTY
| Q1 26 | — | — | ||
| Q4 25 | 80.4% | — | ||
| Q3 25 | 78.7% | 53.6% | ||
| Q2 25 | 82.8% | 54.5% | ||
| Q1 25 | 81.1% | 56.5% | ||
| Q4 24 | 77.4% | — | ||
| Q3 24 | 85.8% | 56.3% | ||
| Q2 24 | 82.0% | 55.7% |
营业利润率NOGRVTY
| Q1 26 | — | — | ||
| Q4 25 | -5.5% | 14.5% | ||
| Q3 25 | -22.6% | 11.7% | ||
| Q2 25 | 24.9% | 12.6% | ||
| Q1 25 | 38.1% | 10.9% | ||
| Q4 24 | 25.8% | 16.3% | ||
| Q3 24 | 57.6% | 14.3% | ||
| Q2 24 | 39.0% | 12.4% |
净利率NOGRVTY
| Q1 26 | -11.6% | — | ||
| Q4 25 | -11.6% | 12.7% | ||
| Q3 25 | -23.2% | 6.7% | ||
| Q2 25 | 14.1% | 7.5% | ||
| Q1 25 | 23.1% | 6.4% | ||
| Q4 24 | 13.9% | 13.0% | ||
| Q3 24 | 39.6% | 13.8% | ||
| Q2 24 | 24.7% | 8.0% |
每股收益（稀释后）NOGRVTY
| Q1 26 | $-0.73 | — | ||
| Q4 25 | $-0.67 | $0.86 | ||
| Q3 25 | $-1.33 | $0.40 | ||
| Q2 25 | $1.00 | $0.46 | ||
| Q1 25 | $1.39 | $0.35 | ||
| Q4 24 | $0.71 | $0.77 | ||
| Q3 24 | $2.96 | $0.77 | ||
| Q2 24 | $1.36 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.3M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $7.3B |
| 总资产 | $5.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NOGRVTY
| Q1 26 | $14.3M | — | ||
| Q4 25 | $14.3M | $919.9M | ||
| Q3 25 | $31.6M | $931.4M | ||
| Q2 25 | $25.9M | $991.8M | ||
| Q1 25 | $33.6M | $1.1B | ||
| Q4 24 | $8.9M | $1.2B | ||
| Q3 24 | $34.4M | $1.2B | ||
| Q2 24 | $7.8M | $2.0B |
总债务NOGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $1.9B | — |
股东权益NOGRVTY
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $7.3B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $2.4B | $7.6B | ||
| Q1 25 | $2.4B | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $2.3B | $7.9B | ||
| Q2 24 | $2.1B | $7.9B |
总资产NOGRVTY
| Q1 26 | $5.4B | — | ||
| Q4 25 | $5.4B | $12.2B | ||
| Q3 25 | $5.5B | $12.1B | ||
| Q2 25 | $5.7B | $12.4B | ||
| Q1 25 | $5.7B | $12.4B | ||
| Q4 24 | $5.6B | $12.4B | ||
| Q3 24 | $5.1B | $12.8B | ||
| Q2 24 | $4.7B | $13.4B |
负债/权益比NOGRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 0.98× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.91× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $312.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $43.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 7.1% | 21.0% |
| 资本支出强度资本支出/营收 | 31.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流NOGRVTY
| Q1 26 | $312.6M | — | ||
| Q4 25 | $312.6M | $182.0M | ||
| Q3 25 | $423.1M | $138.5M | ||
| Q2 25 | $362.1M | $134.3M | ||
| Q1 25 | $407.4M | $128.2M | ||
| Q4 24 | $290.3M | $174.2M | ||
| Q3 24 | $385.8M | $147.9M | ||
| Q2 24 | $340.5M | $158.6M |
自由现金流NOGRVTY
| Q1 26 | $43.2M | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率NOGRVTY
| Q1 26 | 7.1% | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度NOGRVTY
| Q1 26 | 31.5% | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率NOGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 3.64× | 2.49× | ||
| Q1 25 | 2.93× | 3.03× | ||
| Q4 24 | 4.05× | 1.84× | ||
| Q3 24 | 1.29× | 1.57× | ||
| Q2 24 | 2.46× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NOG
| Oil and Gas Sales | $447.7M | 73% |
| Gain on Commodity Derivatives, Net | $159.3M | 26% |
| Other Revenue | $3.1M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
